vs
Ginkgo Bioworks Holdings, Inc.（DNA）与牛津地产（IIPR）财务数据对比。点击上方公司名可切换其他公司
牛津地产的季度营收约是Ginkgo Bioworks Holdings, Inc.的2.0倍（$66.7M vs $33.4M），牛津地产同比增速更快（-13.1% vs -23.8%），过去两年牛津地产的营收复合增速更高（-6.0% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
DNA vs IIPR — 直观对比
营收规模更大
IIPR
是对方的2.0倍
$33.4M
营收增速更快
IIPR
高出10.7%
-23.8%
两年增速更快
IIPR
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $66.7M |
| 净利润 | — | $31.8M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 47.8% |
| 净利率 | — | 47.8% |
| 营收同比 | -23.8% | -13.1% |
| 净利润同比 | — | -20.4% |
| 每股收益（稀释后） | $-1.41 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAIIPR
| Q4 25 | $33.4M | $66.7M | ||
| Q3 25 | $38.8M | $64.7M | ||
| Q2 25 | $49.6M | $62.9M | ||
| Q1 25 | $48.3M | $71.7M | ||
| Q4 24 | $43.8M | $76.7M | ||
| Q3 24 | $89.0M | $76.5M | ||
| Q2 24 | $56.2M | $79.8M | ||
| Q1 24 | $37.9M | $75.5M |
净利润DNAIIPR
| Q4 25 | — | $31.8M | ||
| Q3 25 | $-80.8M | $29.3M | ||
| Q2 25 | $-60.3M | $26.0M | ||
| Q1 25 | $-91.0M | $31.1M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | $-56.4M | $40.2M | ||
| Q2 24 | $-217.2M | $42.0M | ||
| Q1 24 | $-165.9M | $39.4M |
营业利润率DNAIIPR
| Q4 25 | -211.9% | 47.8% | ||
| Q3 25 | -231.8% | 45.5% | ||
| Q2 25 | -132.1% | 45.9% | ||
| Q1 25 | -184.1% | 47.4% | ||
| Q4 24 | -236.3% | 54.7% | ||
| Q3 24 | -62.0% | 54.8% | ||
| Q2 24 | -396.7% | 53.1% | ||
| Q1 24 | -469.1% | 55.7% |
净利率DNAIIPR
| Q4 25 | — | 47.8% | ||
| Q3 25 | -207.9% | 45.3% | ||
| Q2 25 | -121.6% | 41.4% | ||
| Q1 25 | -188.2% | 43.3% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | -63.3% | 52.6% | ||
| Q2 24 | -386.4% | 52.6% | ||
| Q1 24 | -437.3% | 52.3% |
每股收益（稀释后）DNAIIPR
| Q4 25 | $-1.41 | $1.07 | ||
| Q3 25 | $-1.45 | $0.97 | ||
| Q2 25 | $-1.10 | $0.86 | ||
| Q1 25 | $-1.68 | $1.03 | ||
| Q4 24 | $-1.91 | $1.35 | ||
| Q3 24 | $-1.08 | $1.37 | ||
| Q2 24 | $-4.23 | $1.44 | ||
| Q1 24 | $-3.32 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $47.6M |
| 总债务越低越好 | — | $393.7M |
| 股东权益账面价值 | $508.6M | $1.8B |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资DNAIIPR
| Q4 25 | $422.6M | $47.6M | ||
| Q3 25 | $495.5M | $41.9M | ||
| Q2 25 | $559.4M | $104.9M | ||
| Q1 25 | $325.3M | $133.3M | ||
| Q4 24 | $561.6M | $151.2M | ||
| Q3 24 | $616.2M | $172.4M | ||
| Q2 24 | $730.4M | $160.9M | ||
| Q1 24 | $840.4M | $173.5M |
总债务DNAIIPR
| Q4 25 | — | $393.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNAIIPR
| Q4 25 | $508.6M | $1.8B | ||
| Q3 25 | $559.8M | $1.9B | ||
| Q2 25 | $613.0M | $1.9B | ||
| Q1 25 | $647.4M | $1.9B | ||
| Q4 24 | $716.1M | $1.9B | ||
| Q3 24 | $797.9M | $1.9B | ||
| Q2 24 | $833.1M | $1.9B | ||
| Q1 24 | $987.3M | $2.0B |
总资产DNAIIPR
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.2B | $2.3B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.4B | $2.4B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.6B | $2.4B |
负债/权益比DNAIIPR
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $198.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | — |
| 自由现金流率自由现金流/营收 | -142.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 6.22× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DNAIIPR
| Q4 25 | $-47.7M | $198.2M | ||
| Q3 25 | $-31.6M | $45.6M | ||
| Q2 25 | $-40.3M | $48.4M | ||
| Q1 25 | $-51.5M | $54.2M | ||
| Q4 24 | $-42.4M | $258.4M | ||
| Q3 24 | $-103.5M | $64.9M | ||
| Q2 24 | $-84.4M | $64.2M | ||
| Q1 24 | $-89.3M | $71.6M |
自由现金流DNAIIPR
| Q4 25 | $-47.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-59.1M | — | ||
| Q4 24 | $-56.1M | — | ||
| Q3 24 | $-118.6M | — | ||
| Q2 24 | $-111.4M | — | ||
| Q1 24 | $-96.0M | — |
自由现金流率DNAIIPR
| Q4 25 | -142.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -81.2% | — | ||
| Q1 25 | -122.4% | — | ||
| Q4 24 | -128.0% | — | ||
| Q3 24 | -133.2% | — | ||
| Q2 24 | -198.2% | — | ||
| Q1 24 | -252.9% | — |
资本支出强度DNAIIPR
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 17.7% | — |
现金转化率DNAIIPR
| Q4 25 | — | 6.22× | ||
| Q3 25 | — | 1.56× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.75× | ||
| Q4 24 | — | 6.46× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
IIPR
暂无分部数据
